Woolsey Pharmaceuticals Reveals Breakthrough Findings Showing Spread of Toxic TDP-43 Pathology Greatly Reduced in BRAVYL® (oral fasudil) Treated ALS Patients
NEW YORK, Dec. 9, 2024 /PRNewswire/ -- Woolsey Pharmaceuticals, a clinical-stage pharmaceutical company developing BRAVYL (oral fasudil) for the treatment of Amyotrophic Lateral Sclerosis (ALS), announced that a poster by